Sanofi And AstraZeneca Still Lead In RSV But Pfizer Has Chance To Challenge
Pandemic Affected Trial Results
Sanofi and AstraZeneca’s antibody nirsevimab is still likely to reach the market first, but Pfizer could be close behind with superior efficacy results.
You may also be interested in...
GSK looks to have established an efficacy edge over its rivals in developing a vaccine against the respiratory syncytial virus, but analysts expect early 2023 approvals to spark a closely fought contest.
Nirsevimab is set to become the second RSV prophylactic on the market for infants and offers several advantages over its first-to-market competition, but Pfizer’s vaccine rival is fast approaching.
Panel expects to review five respiratory syncytial virus vaccines and vote on one or two of them in June 2023 and others four months later. Sanofi presents results of three clinical trials of its monoclonal antibody nirsevimab, which is on track to be the second RSV prophylaxis for infants.